Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5269969
Max Phase: Preclinical
Molecular Formula: C41H55ClN4O8S
Molecular Weight: 799.43
Associated Items:
ID: ALA5269969
Max Phase: Preclinical
Molecular Formula: C41H55ClN4O8S
Molecular Weight: 799.43
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C(C)C)N2Cc3ccccc3C2=O)c(OCCOCCOCCOCCCCCCCl)c1
Standard InChI: InChI=1S/C41H55ClN4O8S/c1-28(2)37(46-25-32-10-6-7-11-34(32)40(46)49)41(50)45-26-33(47)23-35(45)39(48)43-24-31-13-12-30(38-29(3)44-27-55-38)22-36(31)54-21-20-53-19-18-52-17-16-51-15-9-5-4-8-14-42/h6-7,10-13,22,27-28,33,35,37,47H,4-5,8-9,14-21,23-26H2,1-3H3,(H,43,48)/t33-,35+,37+/m1/s1
Standard InChI Key: UABTZMQNIWDHGQ-JGNAJVFASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 799.43 | Molecular Weight (Monoisotopic): 798.3429 | AlogP: 5.60 | #Rotatable Bonds: 23 |
Polar Surface Area: 139.76 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 13.62 | CX Basic pKa: 2.61 | CX LogP: 3.95 | CX LogD: 3.95 |
Aromatic Rings: 3 | Heavy Atoms: 55 | QED Weighted: 0.09 | Np Likeness Score: -0.58 |
1. Yan J, Li T, Miao Z, Wang P, Sheng C, Zhuang C.. (2022) Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation., 65 (13.0): [PMID:35763424] [10.1021/acs.jmedchem.2c00728] |
Source(1):